Investing in Healthcare Technology: Where Smart Money Is Going

Key Takeaways

• Investing in healthcare technology spans several distinct sub-categories, diagnostics, digital health software, remote monitoring, health data infrastructure, and clinical workflow automation, each with its own regulatory path and risk profile.
• Investing in medical technology and investing in software-only digital health products are regulated differently: physical devices generally follow FDA's three-tier device classification, while software-only products may qualify as Software as a Medical Device (SaMD) under a separate framework.
• Healthcare technology investing carries a regulatory and adoption timeline that most other technology categories do not, since a product often needs both a regulatory clearance and a health system's own procurement approval before it generates revenue.
• Domain expertise in evaluating regulatory pathway, clinical validation, and reimbursement dynamics matters more in this category than generalist technical or market diligence alone.
• The LSM Group applies domain-expert review to every healthcare technology opportunity it brings to its syndicate, structured around a published investment thesis covering diagnostics, applied AI, and health data security.

Healthcare technology has become one of the more active areas of early-stage investing, but the category is broad enough that "investing in healthcare technology" can mean backing an AI-assisted diagnostic imaging startup, a hospital cybersecurity platform, or a remote patient monitoring device, three businesses with almost nothing in common beyond the word "healthcare." The LSM Group works specifically at this intersection of healthcare, applied AI, and life sciences, and this guide breaks down where capital is actually moving within the category, how deals in this space are typically regulated and structured, and what makes the diligence process different from investing in general technology.

This guide focuses specifically on the technology and device side of healthcare investing, diagnostics, digital health, health IT infrastructure, and related categories, rather than pharmaceutical or biotech drug development, which follows a different regulatory pathway of its own.

What Counts as "Healthcare Technology" for Investors

The category spans a wider range of business models than the phrase suggests. Physical diagnostic and monitoring devices, imaging equipment, wearable sensors, at-home testing hardware, follow one regulatory track. Digital health software, clinical decision support tools, AI-assisted diagnostic algorithms, patient engagement platforms, follows a different one, since a piece of software with no physical hardware component can still meet the legal definition of a medical device depending on its intended use. Health IT infrastructure, electronic health record systems, interoperability tools, data security platforms for health systems, sits in a third category that is regulated more around data privacy and security than around clinical safety and effectiveness.

Investing in medical technology historically referred mostly to the first category, physical devices and equipment. The digital health and health IT categories have grown fast enough over the past decade that this combined category today spans all three, and treating them as a single undifferentiated group tends to produce weaker diligence, since the regulatory questions, sales cycles, and risk profiles differ meaningfully between them.

Where Capital Is Actually Moving Within Healthcare Technology

A handful of sub-categories currently account for a disproportionate share of early-stage healthcare technology activity.

• AI-assisted diagnostics. Software that analyzes imaging, lab results, or other clinical data to support a diagnosis, often as a SaMD product rather than a physical device.
• Remote patient monitoring. Devices and platforms that track a patient's condition outside a clinical setting, relevant to chronic disease management and post-acute care.
• Health data interoperability and infrastructure. Tools that let different health systems, providers, and payers exchange patient data, a persistent structural problem in US healthcare that regulatory mandates have pushed toward the front of the queue.
• Data security for health systems and life-sciences infrastructure. Health systems are high-value targets for cyberattacks and hold uniquely sensitive data, making security-specific platforms for this sector a distinct and growing investment category.
• Clinical workflow automation. Software that reduces administrative burden on clinicians and health system staff, an area investors have favored partly because it sidesteps some of the direct-patient-care regulatory questions that diagnostics and monitoring tools face.

These sub-categories map closely onto the focus areas described in The LSM Group's own investment thesis, which centers on diagnostic technology, applied AI in regulated healthcare environments, and data security for health systems and life-sciences infrastructure specifically, rather than healthcare technology as an undifferentiated category.

Who Else Is Deploying Capital in This Category

Independent syndicates and generalist venture investors are not the only source of capital here. Corporate venture arms affiliated with large medical device manufacturers, pharmaceutical companies, and health systems are active investors in the same early-stage deals, often in the exact diagnostic, monitoring, or workflow categories those parent companies eventually want to acquire or integrate into their own product lines.

This changes the picture in two ways. A corporate investor typically brings deep domain expertise and, in some cases, a distribution or channel relationship that a purely financial investor cannot offer, but it can also come with an implicit expectation of exclusivity or a right of first look on a future acquisition, terms worth understanding before accepting a corporate check alongside independent capital. Corporate venture activity in a given sub-category is also a reasonable, if imperfect, signal about where larger industry players expect the category to consolidate, which connects directly to how realistic a company's eventual exit path actually is, one of the four investment criteria described on The LSM Group's investment thesis page alongside specialized knowledge advantage, founder-problem fit, and regulatory-resilient economics.

The Regulatory Layer That Shapes This Category

Regulatory classification is often the single factor most likely to be underweighted in a generalist technology diligence process, and it directly affects both time to revenue and the size of the addressable buyer.

Physical medical devices are classified by the FDA into one of three risk-based classes. Class I devices carry the lowest risk and face only general controls. Class II devices, a large share of diagnostic and monitoring hardware, typically require a 510(k) premarket notification showing substantial equivalence to an already-cleared device. Class III devices, the highest-risk category, generally require full premarket approval, a materially longer and more expensive process.

Software-only products face a parallel but distinct question: whether they meet the FDA's definition of Software as a Medical Device, meaning software intended to perform a medical purpose independently of any hardware device. A clinical decision support tool that informs a diagnosis may qualify as SaMD and require its own regulatory pathway, while an administrative scheduling tool used in the same clinical setting generally would not, since the legal distinction turns on intended medical purpose rather than on the fact that a product happens to touch a healthcare workflow.

Health IT and data infrastructure products face a different regulatory layer entirely, centered on data privacy and security requirements under HIPAA rather than device safety and effectiveness. A company's regulatory burden in this category depends more on what patient data it touches and how, than on any clinical risk classification.

How Healthcare Technology Deals Are Typically Structured

Early-stage healthcare technology investing largely follows the same structural mechanics as other early-stage technology categories: direct equity rounds, convertible instruments at the earliest stages, and increasingly, participation through a syndicate special purpose vehicle rather than a direct check, a structure covered in more detail in our guide on how to be an angel investor. What differs is the milestone structure investors typically track: a regulatory clearance or approval date, a specific health system pilot or contract, and reimbursement code assignment tend to function as the meaningful inflection points in a healthcare technology company's trajectory, in addition to the revenue and user-growth metrics that matter across technology categories generally.

Participation restrictions are the same as elsewhere in early-stage investing: healthcare technology deals structured under Regulation D exemptions are generally limited to accredited investors, a status defined under SEC Rule 501 by income, net worth, or professional licensing thresholds.

Why Domain Expertise Matters More in This Category

A generalist technology investor can reasonably evaluate a horizontal SaaS company's growth metrics, retention, and market size without deep sector expertise. Healthcare technology resists that same generalist approach for a specific reason: the questions that actually determine whether a company succeeds, whether a regulatory pathway is realistic on the timeline management projects, whether a clinical claim is defensible, whether a health system will actually adopt and pay for a product given its own procurement and reimbursement constraints, require domain knowledge that a purely financial or technical background does not provide.

This is the specific gap The LSM Group's model is built to address. Every opportunity is reviewed by a domain expert in that specific sector before it reaches the syndicate, with the resulting Signal Report addressing technical validation, competitive positioning, regulatory risk, and the reviewing expert's own confidence level. More detail on how that expert network operates and how Signal Reports get built is available on our domain experts page.

What to Evaluate Before Investing in a Healthcare Technology Deal

A handful of category-specific questions separate a well-diligenced opportunity from one where the regulatory and commercial risk has not been fully surfaced yet.

• What is the product's actual regulatory status, cleared, under review, or not yet submitted, and does the company's own timeline for its next milestone match what that pathway realistically allows?
• If reimbursement matters to the business model, has a specific reimbursement code already been identified or assigned, or is reimbursement still an open question the company is counting on resolving later?
• Has the product been piloted or contracted with an actual health system, and if so, has that pilot converted into a paying, renewed relationship rather than staying a one-time proof of concept?
• What patient data does the product touch, and what does the company's compliance posture around that data actually look like in practice, not just what its policy documents claim?
• Who are the realistic acquirers or follow-on investors for this specific sub-category, and does the company's own positioning make sense against that group?

Risks Specific to This Category

Several risk factors are distinctive to this category rather than general early-stage investing risk.

• Regulatory timeline risk. A device or software product can clear every technical and clinical milestone a company controls and still face delay through the FDA review process itself, which does not run on a company's fundraising or revenue timeline.
• Adoption and procurement risk. Health systems have long, often multi-department procurement processes, and a product can be clinically validated and regulatory-cleared while still facing a slow, uncertain path to actual purchase and use.
• Reimbursement risk. A product's commercial viability often depends on whether insurers or government payers assign it a reimbursement code, a separate process from regulatory clearance that can lag it by years.
• Data security and privacy exposure. Any product touching patient data carries compliance and breach-liability exposure that a comparable product outside healthcare would not.

None of this is a statement about whether any specific company or investment is likely to succeed. It describes the structural risk factors that apply to the category, which is why the diligence process for a healthcare technology deal typically looks different from diligence on a general technology deal, not just deeper.

Next Steps

Investing in healthcare technology rewards the kind of sector-specific diligence that a generalist process is not built to provide, particularly on regulatory pathway, clinical validation, and reimbursement questions. Investors who want to see how a domain-expert-vetted approach to healthcare, applied AI, and life-sciences deal flow works in practice can apply for membership through The LSM Group's syndicate. There is no membership fee and no obligation to participate in any individual deal. Questions can also be directed to hello@thelsmgroup.com.